Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Revenues	$ 1,920	$ 784
Operating expenses:
Research and development	5,797	7,826
Selling, general and administrative	15,100	3,672
Operating expenses, total	21,035	11,498
Loss from operations	(19,115)	(10,714)
Other income (expense), net:
Interest expense, net	(611)	(315)
Change in fair value of PIPE Warrant liability	(2,396)	2,648
Other income (expense), net	(3,007)	2,333
Net loss	$ (22,122)	$ (8,381)
Net loss per share - basic and diluted	$ (0.81)	$ (0.52)
Weighted average number of common shares outstanding	27,429	16,081
FOTIVDA Product Revenue
Revenues:
Revenues	$ 1,066
Collaboration and Licensing Revenue
Revenues:
Revenues	493	$ 493
Partnership Royalties
Revenues:
Revenues	361	$ 291
Product
Operating expenses:
Cost of products sold	$ 138